LifeStance Health Group, Inc.
LFST- Exchange
- Nasdaq
- Industry
- Services-Health Services
- SEC CIK
- 0001845257
In the last 90 days, LifeStance Health Group, Inc. insiders filed 0 open-market purchases and 4 sales; 291 institutions reported holding it in 13F filings for Q2 2026, worth $4.02B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 11:00 PM ET
Revenue flow, Q3 FY2026
Where the revenue went in Q3 FY2026, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 25, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 7, 2025 | Feb 27, 2025 |
| Revenue | $455.9M | $435.4M | $403.5M | $382.2M† | $363.8M | $345.3M | $333.0M | $325.5M† |
| Operating expenses | $422.8M | $404.7M | $381.2M | $364.1M† | $356.4M | $348.3M | $331.4M | $324.4M† |
| Selling, general and administrative | $113.4M | $108.1M | $100.3M | $94.8M† | $95.6M | $97.4M | $94.4M | $93.7M† |
| Operating income | $33.1M | $30.7M | $22.3M | $18.1M† | $7.41M | -$2.95M | $1.60M | $1.06M† |
| Interest expense | $2.49M | $2.63M | $1.79M | $2.88M† | $2.81M | $2.90M | $3.07M | $9.40M† |
| Income tax | $5.02M | $3.85M | $5.52M | $3.54M† | $3.50M | -$2.15M | -$2.18M | -$1.76M† |
| Net income | $22.4M | $23.6M | $14.2M | $11.7M† | $1.08M | -$3.79M | $709.0K | -$7.11M† |
| Weighted shares, basic | 381.2M | 383.5M | 387.3M | – | 387.0M | 386.7M | 383.3M | – |
| Weighted shares, diluted | 391.2M | 387.3M | 395.1M | – | 388.9M | 386.7M | 390.7M | – |
| Margins and growth | ||||||||
| Operating margin | 7.3% | 7.0% | 5.5% | 4.7% | 2.0% | -0.9% | 0.5% | 0.3% |
| Net margin | 4.9% | 5.4% | 3.5% | 3.1% | 0.3% | -1.1% | 0.2% | -2.2% |
| Revenue growth, year over year | +25.3% | +26.1% | +21.2% | +17.4% | +16.3% | +10.6% | +10.8% | +16.0% |
| Net income growth, year over year | +1,978.5% | – | +1,908.9% | – | – | – | – | – |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025† | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 25, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 7, 2025 | Feb 27, 2025 |
| Cash and equivalents | $218.8M | $225.9M | $194.8M | $248.6M | $203.9M | $188.9M | $134.3M | $154.6M |
| Accounts receivable | $120.9M | $111.0M | $122.9M | $95.7M | $121.1M | $129.5M | $140.4M | $131.8M |
| Total current assets | $376.8M | $378.0M | $355.9M | $416.2M | $360.4M | $358.8M | $304.6M | $312.5M |
| Property, plant and equipment | $166.4M | $164.7M | $161.5M | $161.6M | $162.7M | $160.6M | $163.7M | $166.0M |
| Goodwill | $1.31B | $1.30B | $1.30B | $1.29B | $1.29B | $1.29B | $1.29B | $1.29B |
| Intangible assets | $170.0M | $172.8M | $175.1M | $177.7M | $180.8M | $184.0M | $187.3M | $190.8M |
| Total assets | $2.19B | $2.18B | $2.15B | $2.20B | $2.15B | $2.15B | $2.10B | $2.12B |
| Accounts payable | $5.50M | $11.1M | $4.29M | $6.12M | $12.2M | $7.79M | $7.42M | $7.24M |
| Short-term debt | $14.5M | $14.5M | $18.1M | $14.5M | $12.7M | $10.9M | $9.06M | $7.25M |
| Total current liabilities | $261.1M | $274.8M | $239.7M | $252.0M | $228.6M | $242.3M | $207.4M | $228.9M |
| Long-term debt | $255.5M | $259.0M | $262.5M | $265.9M | $269.4M | $272.9M | $276.3M | $279.8M |
| Total liabilities | $693.9M | $704.3M | $668.5M | $682.9M | $656.2M | $672.9M | $647.6M | $672.0M |
| Shareholders' equity | $1.49B | $1.48B | $1.48B | $1.52B | $1.49B | $1.47B | $1.46B | $1.45B |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q3 FY2026† | Q2 FY2026† | Q1 FY2026 | Q4 FY2025† | Q3 FY2025† | Q2 FY2025† | Q1 FY2025 | Q4 FY2024† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | Nov 5, 2026 | Aug 6, 2026 | May 7, 2026 | Feb 25, 2026 | Nov 6, 2025 | Aug 7, 2025 | May 7, 2025 | Feb 27, 2025 |
| Operating cash flow | $37.0M† | $99.9M† | $33.1M | $57.6M† | $27.3M† | $64.4M† | -$3.09M | $62.3M† |
| Capital expenditures | $14.7M† | $12.0M† | $10.8M | $10.9M† | $10.3M† | $7.75M† | $7.17M | $6.30M† |
| Free cash flow | $22.4M | $87.9M | $22.3M | $46.6M | $17.0M | $56.6M | -$10.3M | $56.0M |
| Depreciation and amortization | $12.1M | $11.3M | $10.4M | $10.3M† | $10.3M | $10.6M | $10.3M | $10.1M† |
| Stock-based compensation | $18.2M† | $19.7M† | $15.2M | $16.7M† | $18.3M† | $21.1M† | $18.6M | $16.1M† |
| Share buybacks | $24.8M† | $48.5M† | $49.1M | – | – | – | – | – |
| Investing cash flow | -$15.2M† | -$17.9M† | -$13.9M | -$10.9M† | -$10.3M† | -$7.75M† | -$7.17M | -$6.30M† |
| Financing cash flow | -$28.9M† | -$50.9M† | -$73.0M | -$1.91M† | -$2.02M† | -$2.05M† | -$9.97M | -$4.06M† |
| Net change in cash | -$7.13M† | $31.1M† | -$53.8M | $44.7M† | $15.0M† | $54.6M† | -$20.2M | $52.0M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 4.0% | 4.5% | 3.8% | 4.4% | 5.0% | 6.1% | 5.6% | 5.0% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 28, 2026 | 380.2M | −2.3% | SEC |
| Jul 29, 2026 | 382.1M | −1.8% | SEC |
| Apr 29, 2026 | 387.8M | −0.3% | SEC |
| Feb 17, 2026 | 389.8M | +1.4% | SEC |
| Oct 29, 2025 | 389.0M | +1.7% | SEC |
| Jul 30, 2025 | 388.9M | +1.7% | SEC |
| Apr 30, 2025 | 388.9M | +1.7% | SEC |
| Feb 19, 2025 | 384.6M | +1.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.